Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
A Mixed Bag In Pharma And Mixed Messaging In Oncology Irks Investors
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.
